Literature DB >> 33609142

MicroRNA-301a-3p promotes diabetic retinopathy via regulation of six-transmembrane epithelial antigen of prostate 4.

Yingmin Wang1, Lijuan Gao2, Zhili Li3, Xingyou Ma4.   

Abstract

OBJECTIVE AND
DESIGN: Diabetic retinopathy (DR) is one of the most serious microvascular complications of diabetes mellitus (DM). MicroRNAs (miRNAs) have been discovered to play a crucial role in DR, but the mechanisms underlying the effects of miR-301a-3p on DR are poorly understood. This paper was designed to explore the possible role of miR-301a-3p in DR.
METHODS: The diabetic rat model was established by a single intraperitoneal injection of streptozotocin (STZ). The effects of miR-301a-3p on the biological functions of HRECs were determined through a series of experiments in vitro/vivo.
RESULTS: The results revealed that interference with miR-301a-3p could decrease the expressions of inflammatory factors and apoptosis in the retinal tissue of DR. Furthermore, it can alleviate the oxidative stress in DR serum, reduce VEGF expression, increase endothelial cell marker expression, and inhibit (High Glucose) HG-induced apoptosis of HRECs. Six-transmembrane epithelial antigen of prostate 4 (STEAP4) was the target of miR-301a-3p. All the effects of miR-301a-3p in DR model were reversed by STEAP4 inhibitor.
CONCLUSION: miR-301a-3p promotes diabetic retinopathy via regulation of STEAP4. The findings in this study may provide a vital reference for the drug research and development in DR treatment.

Entities:  

Keywords:  Diabetic retinopathy; MiR-301a-3p; STEAP4

Year:  2021        PMID: 33609142     DOI: 10.1007/s00011-020-01431-0

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  5 in total

1.  Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN.

Authors:  Xiang Xia; Kundong Zhang; Guangtao Luo; Gang Cen; Jun Cao; Kejian Huang; Zhengjun Qiu
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

2.  VEGF-initiated blood-retinal barrier breakdown in early diabetes.

Authors:  T Qaum; Q Xu; A M Joussen; M W Clemens; W Qin; K Miyamoto; H Hassessian; S J Wiegand; J Rudge; G D Yancopoulos; A P Adamis
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-09       Impact factor: 4.799

3.  Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells.

Authors:  Polyxenie E Spoerri; Aqeela Afzal; Sergio Li Calzi; Lynn C Shaw; Jun Cai; Hao Pan; Michael Boulton; Maria B Grant
Journal:  Mol Vis       Date:  2006-01-12       Impact factor: 2.367

4.  Effect of intravitreal conbercept treatment before vitrectomy in proliferative diabetic retinopathy.

Authors:  Jian-Bo Mao; Han-Fei Wu; Yi-Qi Chen; Shi-Xin Zhao; Ji-Wei Tao; Yun Zhang; Bin Zheng; Lin Wang; Li-Jun Shen
Journal:  Int J Ophthalmol       Date:  2018-07-18       Impact factor: 1.779

Review 5.  Diabetes and retinal vascular dysfunction.

Authors:  Eui Seok Shin; Christine M Sorenson; Nader Sheibani
Journal:  J Ophthalmic Vis Res       Date:  2014 Jul-Sep
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.